J Psychoactive Drugs. 2014 Jan-Mar;46(1):20-6. doi: 10.1080/02791072.2014.873688.
This essay describes the founding of the Heffter Research Institute in 1993 and its development up to the present. The Institute is the only scientific research organization dedicated to scientific research into the medical value of psychedelics, and it has particularly focused on the use of psilocybin. The first clinical treatment study was of the value of psilocybin in obsessive-compulsive disorder. Next was a UCLA study of psilocybin to treat end-of-life distress in end-stage cancer patients. While that study was ongoing, a trial was started at Johns Hopkins University (JHU) to study the efficacy of psilocybin in treating anxiety and depression resulting from a cancer diagnosis. Following the successful completion of the UCLA project, a larger study was started at New York University, which is near completion. A pilot study of the value of psilocybin in treating alcoholism at the University of New Mexico also is nearing completion, with a larger two-site study being planned. Other studies underway involve the use of psilocybin in a smoking cessation program and a study of the effects of psilocybin in long-term meditators, both at JHU. The institute is now planning for a Phase 3 clinical trial of psilocybin to treat distress in end-stage cancer patients.
本文描述了 1993 年海弗特研究所的成立及其发展至今的情况。该研究所是唯一一家专门从事迷幻药医学价值科学研究的科研机构，尤其专注于使用裸盖菇素。第一项临床治疗研究是评估裸盖菇素治疗强迫症的价值。接下来是加利福尼亚大学洛杉矶分校的一项研究，旨在用裸盖菇素治疗晚期癌症患者临终前的痛苦。在该研究进行的同时，约翰霍普金斯大学（JHU）开始了一项关于裸盖菇素治疗癌症诊断引起的焦虑和抑郁的疗效的试验。在完成加利福尼亚大学洛杉矶分校的项目后，在纽约大学启动了一项更大规模的研究，该研究已接近完成。新墨西哥大学也即将完成一项关于裸盖菇素治疗酗酒价值的试点研究，计划进行更大规模的双地点研究。其他正在进行的研究包括在戒烟计划中使用裸盖菇素和研究裸盖菇素对长期冥想者的影响，这两项研究都在 JHU 进行。该研究所目前正在计划进行第三阶段的裸盖菇素临床试验，以治疗晚期癌症患者的痛苦。
